EE599 Cost-Effectiveness Analysis of Trastuzumab Emtansine for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in Greece

Abstract

Approximately 7,770 new patients are diagnosed annually with breast cancer in Greece and 25% of them have human epidermal growth factor receptor 2 (HER2+) disease. 49% of newly diagnosed HER2+ patients have early-stage breast cancer (eBC). Based on a physician survey (N=95), 44% of patients receive neo-adjuvant treatment, of whom 33.7% have residual disease and require additional treatment in the adjuvant setting. The objective of this study was to evaluate the cost-effectiveness of trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ eBC after neoadjuvant taxane-based and HER2-targeted therapy, from the third-party payer perspective (EOPYY) in Greece.